Glenmark Launches Affordable Semaglutide GLIPIQⓇ To Expand Diabetes Care Access In India, Sets New Cost Benchmark For GLP-1 Therapy With Flexible Dosing Options

Glenmark Pharmaceuticals Ltd announced the launch of GLIPIQⓇ (semaglutide) in India for the treatment of Type 2 Diabetes Mellitus, aiming to make GLP-1 therapy significantly more affordable and accessible. The introduction addresses a key barrier in diabetes care, where patients often delay advanced injectable treatments due to high costs and complexity.

GLIPIQⓇ has been approved by the Central Drugs Standard Control Organisation following a multicentre, randomised, active-controlled Phase III clinical trial conducted in India that demonstrated favourable safety and efficacy outcomes in local patients. The therapy is available in both vial and pre-filled pen formats, providing physicians and patients with flexible administration options.

Commenting on the launch, Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, “Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQⓇ, we are setting a new affordability benchmark for GLP-1 therapy, with weekly treatment starting at ₹325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing. 

A key differentiator is the vial-based presentation paired with dose-specific syringes, designed to support physician-guided dose adjustments and improve early-stage treatment management. This format provides a more cost-effective pathway, improving adherence and enabling broader access to GLP-1 therapy. The estimated weekly treatment cost ranges between ₹325 and ₹440, substantially lowering the financial threshold for initiating this class of medicines in India.

In addition to affordability, Glenmark is launching ‘Sankalp’, a patient support program to assist with therapy initiation, injection comfort, and long-term adherence. The pre-filled pen option complements the vial format by offering convenience for sustained self-administration. Available in multiple strengths, GLIPIQⓇ supports structured treatment pathways and reflects the growing role of semaglutide in managing diabetes alongside comorbid conditions such as obesity, cardiovascular disease, heart failure, and chronic kidney disease.